SCHEMBL464744

SCHEMBL464744

C=CC(=O)C=C.CC(C)(C)OC(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.65
PPARG P37231 3/20 0.60
BCL2 P10415 1/20 0.59
ITGB3 P05106 3/20 0.59
ITGA2B P08514 3/20 0.59
ACE P12821 2/20 0.57
YAP1 P46937 1/20 0.56
PPARA Q07869 2/20 0.55
MME P08473 1/20 0.54
CPA1 P15085 1/20 0.54
ACE2 Q9BYF1 1/20 0.54
GPR34 Q9UPC5 1/20 0.53
HDAC8 Q9BY41 1/20 0.52
REN P00797 1/20 0.51
CTSS P25774 2/20 0.51
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
CTSK P43235 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193474 0.93 PTPN1 (0.73) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL193473 0.93 PTPN1 (0.73) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL2891538 0.93 PTPN1 (0.73) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL28267499 0.88 PTPN1 (0.77) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL28267496 0.88 PTPN1 (0.77) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL12706402 0.86 BCL2 (0.62) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL27575100 0.86 BCL2 (0.59) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL7320039 0.84 ACE (0.58) PTPN1PPARGBCL2ITGB3ITGA2B
Phenylalanine Methyl Ester SCHEMBL28119144 0.84 PTPN1 (0.63) PTPN1PPARGBCL2ITGB3ITGA2B
SCHEMBL6161729 0.84 BCL2 (0.64) PTPN1PPARGBCL2ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
EP-1686113-B1 Inhibitors of aspartyl protease VERTEX PHARMA (US) 2011-11-23 EP disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 PTPN1 1557/4885PPARG 4753/4885BCL2 1781/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 PTPN1 1557/4885PPARG 4753/4885BCL2 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.